
Survival Outcomes of Early-Stage High Grade Serous Ovarian Cancer Using the SEER Cancer Database

Kevin Kremer

10/9/2020

OS based on stage

Survival Stratified by TNM Stage




```
## Pairwise comparisons using Log-Rank test
##
## data: HGS and TNM.Stage
##
## T1NOMO T1NxMO T1N1MO
## T1NxMO 1.2e-13 - -
## T1N1MO 7.8e-05 0.16627 -
```

```
## Any M1 < 2e-16 0.00019 1.6e-05
##
## P value adjustment method: BH</pre>
```

For presumed early-stage HGSOC, does adequacy of LN evaluation matter?


Survival of presumed early-stage HGSOC stratified by lymph node dissection



##
Pairwise comparisons using Log-Rank test
##
data: HGS.ES and Nodes_Ex
##
Adequate Inadequate
Inadequate 0.2 ## None 1.1e-12 1.9e-06
##
P value adjustment method: BH

Lymphadenectomy	Count
Adequate	514
Inadequate	278
None	274






```
## coxph(formula = Surv(SurvMonths, COD) ~ Nodes_Ex, data = HGS.ES)
##
    n= 1066, number of events= 181
##
##
##
                     coef exp(coef) se(coef)
                                              z Pr(>|z|)
0.193
## Nodes_ExNone
                  1.1809
                            3.2574
                                   0.1726 6.841 7.85e-12 ***
## ---
## Signif. codes: 0 '*** 0.001 '** 0.01 '* 0.05 '.' 0.1 ' 1
                   exp(coef) exp(-coef) lower .95 upper .95
##
                                                  1.956
## Nodes_ExInadequate
                       1.307
                                0.7653
                                         0.8731
## Nodes_ExNone
                       3.257
                                0.3070
                                         2.3224
                                                   4.569
##
## Concordance= 0.652 (se = 0.02)
## Likelihood ratio test= 50.25 on 2 df,
                                       p=1e-11
## Wald test
                    = 52.95 on 2 df,
                                      p=3e-12
## Score (logrank) test = 58.48 on 2 df,
```


In patient's without LND, does adding chemo change their survival?

Survival of presumed early-stage HGSOC with chemotherapy



Positive Nodes	Count
No	593
Unk	177







```
## coxph(formula = Surv(SurvMonths, COD) ~ Nodes_Pos, data = HGS.ES.chemo)
##
   n= 770, number of events= 118
##
##
##
              coef exp(coef) se(coef)
                                      z Pr(>|z|)
## Signif. codes: 0 '*** 0.001 '** 0.01 '* 0.05 '.' 0.1 ' ' 1
##
             exp(coef) exp(-coef) lower .95 upper .95
##
              3.226
                      0.31
                                 2.243
## Nodes_PosUnk
                                           4.64
## Concordance= 0.639 (se = 0.024)
## Likelihood ratio test= 36.52 on 1 df, p=2e-09
## Wald test = 39.93 on 1 df, p=3e-10
## Score (logrank) test = 44.67 on 1 df, p=2e-11
```

Survival difference between N0 patients with and without chemotherapy

Survival of T1N0M0 patients stratified by receipt of chemotherapy



Received Chemotherapy	Count
Yes	593
No/Unknown	199



```
## coxph(formula = Surv(SurvMonths, COD) ~ Chemo, data = HGS.NO)
##
    n= 792, number of events= 97
##
##
                   coef exp(coef) se(coef)
##
                                              z Pr(>|z|)
## ChemoNo/Unknown 0.2746 1.3160 0.2168 1.266
                                                   0.205
##
##
                 exp(coef) exp(-coef) lower .95 upper .95
## ChemoNo/Unknown 1.316 0.7599
                                        0.8603
                                                   2.013
## Concordance= 0.53 (se = 0.025)
## Likelihood ratio test= 1.55 on 1 df,
                                        p = 0.2
## Wald test
                    = 1.6 on 1 df, p=0.2
## Score (logrank) test = 1.61 on 1 df, p=0.2
```